Your browser doesn't support javascript.
loading
Safety and immunogenicity of sequential administration of PCV13 followed by PPSV23 in pneumococcal vaccine-naïve adults aged ≥ 65 years: Comparison of booster effects based on intervals of 0.5 and 1.0 year.
Azuma, Momoyo; Oishi, Kazunori; Akeda, Yukihiro; Morino, Saeko; Motoki, Yumi; Hanibuchi, Masaki; Nishioka, Yasuhiko.
Affiliation
  • Azuma M; Department of Infection Control and Prevention, Tokushima University Hospital, Japan. Electronic address: azumm@tokushima-u.ac.jp.
  • Oishi K; Toyama Institute of Health, Toyama, Japan.
  • Akeda Y; Department of Bacteriology I, National Institute of Infectious Diseases, Tokyo, Japan; Division of Infection Control and Prevention, Osaka University Hospital, Osaka University, Osaka, Japan; Department of Infection Control and Prevention, Osaka University Graduate School of Medicine, Osaka, Japan;
  • Morino S; Centre for Surveillance, Immunization and Epidemiologic Research, National Institute of Infectious Diseases, Tokyo, Japan.
  • Motoki Y; Hakuai Memorial Hospital.
  • Hanibuchi M; Department of Community Medicine for Respirology, Hematology and Metabolism Graduate School of Biomedical Sciences, Tokushima University, Japan.
  • Nishioka Y; Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan.
Vaccine ; 41(5): 1042-1049, 2023 01 27.
Article in En | MEDLINE | ID: mdl-36593171
ABSTRACT

OBJECTIVE:

An open-label study was conducted to compare the safety and immunogenicity of a sequential administration of 13-valent pneumococcal conjugate vaccine (PCV13) followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23) between an interval of 0.5 (0.5-y) and 1 year (1.0-y) in adults aged ≥ 65 years.

METHODS:

Pneumococcal vaccine-naïve adults aged ≥ 65 years (n = 129) received a sequential administration with an interval of 0.5-y or 1.0-y or received a single administration of PPSV23 (single PPSV23). We evaluated the immunogenicity before and 1 month after each vaccination and at 0.5-y intervals for 2 years. The primary endpoint was the increase in geometric mean fold rises (GMFRs) of immunoglobulin G (IgG) or opsonophagocytic activity (OPA) for eight common serotypes one month after one dose of PPSV23. The secondary endpoint was the safety profile for one dose of PPSV23.

RESULTS:

One month after administration of PPSV23, the GMFRs of IgG considerably increased for five of eight serotypes in the 1.0-y interval group, whereas the GMFRs of IgG considerably increased for two serotypes in the 0.5-y interval group. Furthermore, GMFRs of OPA markedly increased for all eight serotypes in the 1.0-y interval group, while GMFRs of OPA markedly increased for four serotypes in the 0.5-y interval group. At 2 years after initial vaccination, GMFRs of IgG or OPA were higher for all serotypes, except for serotype 3, than those in the single PPSV23 group irrespective of intervals. No significant difference was found in the frequencies of local reactions of all grades between the two intervals.

CONCLUSIONS:

The 1.0-y interval provided better booster effects induced by PPSV23 than those of the 0.5-y interval in a sequential administration in pneumococcal vaccine-naïve adults aged ≥ 65 years. No difference was found in the safety profile between both intervals.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pneumococcal Infections / Streptococcus pneumoniae Type of study: Clinical_trials Limits: Humans Language: En Journal: Vaccine Year: 2023 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pneumococcal Infections / Streptococcus pneumoniae Type of study: Clinical_trials Limits: Humans Language: En Journal: Vaccine Year: 2023 Document type: Article